2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

嵌合抗原受体 医学 细胞因子释放综合征 淋巴瘤 CD19 免疫疗法 B细胞 免疫学 T细胞 肿瘤科 Blinatumoab公司 抗原 癌症研究 内科学 癌症 免疫系统 抗体
作者
Ping Li,Yang Liu,Yun Liang,Jian Bo,Sujun Gao,Yongxian Hu,Yu Hu,He Huang,Xiao‐Jun Huang,Hongmei Jing,Xiaoyan Ke,Jianyong Li,Yuhua Li,Qifa Liu,Peihua Lu,Heng Mei,Ting Niu,Yongping Song,Yuqin Song,Liping Su
出处
期刊:Cancer biology and medicine [Chinese Anti-Cancer Association]
卷期号:20 (2): 129-146 被引量:17
标识
DOI:10.20892/j.issn.2095-3941.2022.0585
摘要

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
秦艽完成签到,获得积分0
刚刚
刚刚
1秒前
1秒前
敏感初露发布了新的文献求助10
1秒前
赘婿的应助被sail采纳,获得30
1秒前
1秒前
家伟发布了新的文献求助10
2秒前
诚心初晴完成签到,获得积分10
2秒前
2秒前
2秒前
梓泽丘墟完成签到,获得积分0
3秒前
3秒前
田様的应助被等待的紫伊采纳,获得10
4秒前
Hello的应助被dddddddd采纳,获得10
4秒前
zhuo完成签到,获得积分10
4秒前
4秒前
4秒前
Lyndonz7u发布了新的文献求助10
4秒前
华仔的应助被kkkkk采纳,获得10
5秒前
小马完成签到,获得积分10
5秒前
zhonglv7的应助被调皮摇伽采纳,获得10
5秒前
5秒前
研友_VZG7GZ的应助被shancui采纳,获得10
5秒前
6秒前
Clearday发布了新的文献求助10
6秒前
Ray的应助被敏感初露采纳,获得10
6秒前
打打的应助被敏感初露采纳,获得10
6秒前
Rong完成签到,获得积分10
6秒前
0x1orz完成签到,获得积分10
6秒前
6秒前
linjong发布了新的文献求助10
6秒前
yin2完成签到,获得积分20
6秒前
K先生发布了新的文献求助10
7秒前
7秒前
文静的笑槐完成签到,获得积分10
9秒前
Chris_Du完成签到,获得积分10
9秒前
夹心大王发布了新的文献求助10
9秒前
悠然发布了新的文献求助10
9秒前
小y完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168872
求助须知:如何正确求助?哪些是违规求助? 9561930
关于积分的说明 21763934
捐赠科研通 7760585
什么是DOI,文献DOI怎么找? 3430171
关于科研通互助平台的介绍 2554053
邀请新用户注册赠送积分活动 2474806